Immunotherapy News and Research

Latest Immunotherapy News and Research

FDA grants Orphan Drug Designation to TxCell's Col-Treg for treatment of autoimmune uveitis

TxCell SA, a biotechnology company developing innovative, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic inflammatory and autoimmune diseases, announces today that the U.S. Food and Drug Administration's Office of Orphan Products Development has granted Orphan Drug Designation (ODD) to TxCell's Col-Treg, a personalized T cell immunotherapy using collagen-II specific regulatory T-cells, for the treatment of chronic non-infectious uveitis.

15 Sep 2015

Aridis' AR-301 granted FDA Fast Track Designation for treatment of pneumonia caused by S. aureus

Aridis Pharmaceuticals, Inc., a biopharmaceutical company applying proprietary technologies to produce novel anti-infectives and immunotherapies for infectious diseases, announced today that the U.S. Food and Drug Administration granted Fast Track Designation to AR-301, the Company's fully human anti-Staphylococcal alpha-toxin IgG1 monoclonal antibody (mAb).

11 Sep 2015

New collaboration may allow researchers to develop potential gene therapies for pediatric diseases

A new collaboration between Seattle Children's Research Institute and bluebird bio, Inc., a biotechnology company based in Cambridge, Mass. and Seattle, will allow researchers to develop potentially transformative gene therapies for severe genetic and rare pediatric diseases. The collaboration supports pediatric researchers in Seattle who will work with bluebird bio scientists and the company's gene editing technology to research potential cures for genetic pediatric diseases.

11 Sep 2015

CureVac announces official launch of U.S. operations in Cambridge, MA

CureVac, a clinical-stage biopharmaceutical company pioneering the field of mRNA-based technology, today announced the official launch of its U.S. operations in Cambridge, MA, as the company advances the development of its proprietary mRNA platform technology and multiple, clinical-stage mRNA therapeutics and vaccines.

10 Sep 2015

Penns' Abramson Cancer Center rated as 'exceptional' by NCI

The University of Pennsylvania's Abramson Cancer Center (ACC) has received an "exceptional" rating by the National Cancer Institute during an extensive peer-review process for its five-year competitive research support grant. The rating is the highest possible for an NCI cancer center.

9 Sep 2015

MD Anderson's Jim Allison named winner of 2015 Lasker-DeBakey Clinical Medical Research Award

For inventing a completely new way to strike cancer by unlocking a shackled immune system attack, Jim Allison, Ph.D., chair of Immunology at The University of Texas MD Anderson Cancer Center, will receive the nation's highest honor for clinical medical research.

9 Sep 2015

Oxis Biotech executes worldwide license agreement to develop, commercialize novel cancer therapy

Oxis Biotech, Inc., a wholly owned subsidiary of Oxis International, Inc., announced today the execution of an exclusive worldwide license agreement to further develop and commercialize DT2219ARL, a novel therapy for the treatment of various human B cell cancers, leukemias and lymphomas.

8 Sep 2015

NanoPass to supply MicronJet600 device for use with Immune Design's ZVex discovery platform

NanoPass Technologies Ltd., a pioneer in intradermal delivery solutions for immunotherapies, announced today that it has entered into a clinical supply and support agreement for the supply of MicronJet600, its microneedle delivery device, for use with Immune Design's oncology immunotherapy products from its ZVex discovery platform.

8 Sep 2015

Helsinn, BIAL sign exclusive distribution and licence agreement for Anamorelin

Helsinn, the Swiss Group focused on building quality cancer care, and BIAL - Portela & Ca. S.A., one of the largest Iberian pharmaceutical companies, today announce that they have entered into an agreement for the exclusive distribution and licence rights to Anamorelin in Spain, Portugal, Angola and Mozambique.

8 Sep 2015

AstraZeneca presents lung cancer research data at WCLC 2015

Data will be reported from across AstraZeneca’s industry-leading lung cancer portfolio at the World Conference on Lung Cancer 2015, beginning this weekend in Denver, Colorado.

8 Sep 2015

Desmoplasmic melanoma may possess unprecedented burden of gene mutations, say UCSF scientists

A rare, deadly form of skin cancer known as desmoplasmic melanoma (DM) may possess the highest burden of gene mutations of any cancer, suggesting that immunotherapy may be a promising approach for treatment, according to an international team led by UC San Francisco scientists. One of these mutations, never before observed in any cancer, may shield nascent DM tumors from destruction by the immune system and allow further mutations to develop.

7 Sep 2015

New treatments under development for adults with coeliac disease may also benefit children

A new study has revealed childhood coeliac disease mirrors the condition in adults, increasing the possibility a coeliac disease therapy that could enable patients to eat gluten again will work in children.

4 Sep 2015

Aspirin may help boost effectiveness of cancer treatment

Giving cancer patients aspirin at the same time as immunotherapy could dramatically boost the effectiveness of the treatment, according to new research published in the journal Cell today (Thursday).

3 Sep 2015

Adaptimmune doses first patient in expanded Phase I/II trial of T-cell therapy for synovial sarcoma

Adaptimmune Therapeutics plc, a clinical stage biopharmaceutical company focused on the use of T-cell therapy to treat cancer, today announced that the first patient has been dosed in its expanded Phase I/II trial of its affinity enhanced T-cell receptor therapeutic targeting the NY-ESO-1 cancer antigen in synovial sarcoma patients.

3 Sep 2015

UCLA scientists develop promising new combination treatment for glioblastoma

UCLA scientists have developed a potentially promising new combination therapy for glioblastoma, the deadliest form of brain cancer.

2 Sep 2015

Experts to discuss research on lupus at world congress organized by MedUni Vienna

Lupus is an autoimmune disease with so many different symptoms that it is often difficult to diagnose and to treat. Despite huge medical advances over the last few years, lupus is incurable. Modern, individually tailored therapeutic approaches are aimed at helping sufferers. The world congress organized by MedUni Vienna brings experts from more than 80 countries together in Vienna from 2 to 6 September to discuss the latest research results and therapies.

1 Sep 2015

Affinity tuning can make CAR T cells spare normal cells and attack cancer cells

A new development in engineering chimeric antigen receptor (CAR) T cells, called affinity tuning, can make the CAR T cells spare normal cells and better recognize and attack cancer cells, which may help lower the toxicity associated with this type of immunotherapy when used against solid tumors, according to a preclinical study.

1 Sep 2015

Regen BioPharma develops novel means of delivering RGBP-248 gene silencing nucleic acid to liver tumors

Regen BioPharma, Inc. announced today development of a novel means of delivering its patented (US Patent 8,263,571) gene silencing nucleic acid, RGBP-248, to liver tumors utilizing a clinically approved formulation as delivery system. The product in development overcomes previous hurdles with gene silencing therapeutics in which the gene silencing drug had to be delivered throughout the whole body.

31 Aug 2015

Adaptive immune system plays active role in guiding development of mammary glands

In experiments with mouse tissue, UC San Francisco researchers have discovered that the adaptive immune system, generally associated with fighting bacterial and viral infections, plays an active role in guiding the normal development of mammary glands, the only organs--in female humans as well as mice--that develop predominately after birth, beginning at puberty.

28 Aug 2015

Researchers find way to trigger 'virus alert' that may help boost drug's ability to prevent cancer cells

Working with human cancer cell lines and mice, researchers at the Johns Hopkins Kimmel Cancer Center and elsewhere have found a way to trigger a type of immune system "virus alert" that may one day boost cancer patients' response to immunotherapy drugs. An increasingly promising focus of cancer research, the drugs are designed to disarm cancer cells' ability to avoid detection and destruction by the immune system.

27 Aug 2015

Immunotherapy News and Research

Latest Immunotherapy News and Research

FDA grants Orphan Drug Designation to TxCell's Col-Treg for treatment of autoimmune uveitis

Aridis' AR-301 granted FDA Fast Track Designation for treatment of pneumonia caused by S. aureus

New collaboration may allow researchers to develop potential gene therapies for pediatric diseases

CureVac announces official launch of U.S. operations in Cambridge, MA

Penns' Abramson Cancer Center rated as 'exceptional' by NCI

MD Anderson's Jim Allison named winner of 2015 Lasker-DeBakey Clinical Medical Research Award

Oxis Biotech executes worldwide license agreement to develop, commercialize novel cancer therapy

NanoPass to supply MicronJet600 device for use with Immune Design's ZVex discovery platform

Helsinn, BIAL sign exclusive distribution and licence agreement for Anamorelin

AstraZeneca presents lung cancer research data at WCLC 2015

Desmoplasmic melanoma may possess unprecedented burden of gene mutations, say UCSF scientists

New treatments under development for adults with coeliac disease may also benefit children

Aspirin may help boost effectiveness of cancer treatment

Adaptimmune doses first patient in expanded Phase I/II trial of T-cell therapy for synovial sarcoma

UCLA scientists develop promising new combination treatment for glioblastoma

Experts to discuss research on lupus at world congress organized by MedUni Vienna

Affinity tuning can make CAR T cells spare normal cells and attack cancer cells

Regen BioPharma develops novel means of delivering RGBP-248 gene silencing nucleic acid to liver tumors

Adaptive immune system plays active role in guiding development of mammary glands

Researchers find way to trigger 'virus alert' that may help boost drug's ability to prevent cancer cells

Exploring Strategies for Targeting Kinases in Innate Immunity eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Immunotherapy News and Research

Latest Immunotherapy News and Research

Exploring Strategies for Targeting Kinases in Innate Immunity eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in